Introduction {#Sec1}
============

Angiogenesis, the formation of new blood vessels from existing ones, is an essential process if solid tumours are to grow beyond 2--3 mm^3^, since diffusion is no longer sufficient to supply the tissue with oxygen and nutrients \[[@CR1]\]. Tumour-induced angiogenesis is a complex multistep process that follows a characteristic cascade of events mediated and controlled by growth factors, cellular receptors and adhesion molecules \[[@CR2]--[@CR4]\].

Activated endothelial cells express the integrin α~v~β~3~ receptor, whereas this integrin receptor is absent on quiescent endothelial cells. In addition, α~v~β~3~ is expressed on the cell membrane of various tumour cell types such as ovarian cancer, neuroblastoma, breast cancer and melanoma. α~v~β~3~ Integrin expressed on endothelial cells modulates cell migration and survival during angiogenesis, whereas α~v~β~3~ integrin expressed on carcinoma cells potentiates metastasis by facilitating invasion and movement across blood vessels. Due to this restricted expression of α~v~β~3~ in tumours, α~v~β~3~ is considered a suitable candidate for tumour targeting \[[@CR5]\]. Radiolabelled ligands for this integrin could be used as tracers to noninvasively visualise α~v~β~3~ expression in tumours. Noninvasive visualisation of α~v~β~3~ expression might provide information about the angiogenic process and the responsiveness of a tumour to antiangiogenic drugs. Furthermore, noninvasive determination of α~v~β~3~ expression potentially can be used to monitor the effect of antiangiogenic drugs in patients.

The α~v~β~3~ integrin is a transmembrane protein consisting of two noncovalently bound subunits, α and β. This integrin can bind to the arginine-glycine-aspartic acid (RGD) amino acid sequence present in extracellular matrix proteins such as vitronectin, fibrinogen and laminin \[[@CR6]\]. Based on the RGD tripeptide sequence a series of small peptides have been designed to antagonise the function of the α~v~β~3~ integrin \[[@CR7]\]. Especially the cyclic peptide derivatives have a relatively high affinity for the α~v~β~3~ integrin. Radiolabelled cyclic RGD peptides have the potential for early detection of rapidly growing tumours and noninvasive visualisation of tumour metastasis and therapeutic response in cancer patients.

Over the last several years, significant progress has been made in the development of α~v~β~3~-targeting radiotracers for the visualisation of α~v~β~3~ expression in tumours by single photon emission computed tomography (SPECT) and positron emission tomography (PET).

Haubner and coworkers developed the first α~v~β~3~-specific PET tracer \[^18^F\]Galacto-RGD \[[@CR8]\], a glycosylated cyclic pentapeptide, which demonstrated that PET with \[^18^F\]Galacto-RGD enables receptor-specific monitoring of α~v~β~3~ expression in murine tumour models. It was the first PET tracer applied in patients with cancer which could successfully image α~v~β~3~ expression with good tumour to background ratios \[[@CR9]\]. In addition, a strong correlation between tracer uptake and α~v~β~3~ expression was observed \[[@CR10]\]. In the mean time, another RGD-based PET tracer, \[^18^F\]AH111585, has been developed and evaluated in breast cancer patients \[[@CR11]\]. \[^18^F\]AH111585 was demonstrated to be safe and metabolically stable and could visualise tumours in breast cancer patients. Although both ^18^F-labelled RGD monomers bind specifically to the α~v~β~3~ integrin, their clinical translation is partly hampered by the time-consuming multistep ^18^F-labelling procedure and the necessity of a cyclotron facility to produce this PET isotope.

An interesting alternative is the use of the generator-produced radionuclide ^68^Ga. The application of ^68^Ga-labelled peptides has attracted considerable interest for cancer imaging, because of its physical characteristics \[[@CR12]\]. ^68^Ga decays at 89% through positron emission of 1.92 MeV (max. energy) and can be eluted from an in-house ^68^Ge/^68^Ga generator (^68^Ge, *T*~1/2~ = 270.8 days) which renders it independent of an on-site cyclotron. Furthermore, with a half-life of 68 min, ^68^Ga is also compatible with the pharmacokinetics of many peptides.

Recently, Decristoforo et al. compared the in vitro and in vivo properties of \[^68^Ga\]DOTA-RGD with that of the corresponding \[^111^In\]DOTA-RGD \[[@CR13]\]. They found that especially in the blood and also in tumour the uptake of the ^68^Ga-labelled peptide was higher than the ^111^In-labelled counterpart which could be explained by different complex stabilities for the Ga-DOTA and the In-DOTA complexes, resulting in transmetallation of gallium to transferrin. The group in Stanford conjugated RGD monomers and multimers to *p*-SCN-Bn-NOTA and labelled them with ^68^Ga for imaging integrin expression in a U87MG glioblastoma xenograft model \[[@CR14], [@CR15]\]. They clearly observed by increasing RGD units an increase in α~v~β~3~ affinity and tumour uptake. In addition, it was possible to increase the α~v~β~3~ receptor-binding affinity of the RGD dimer by coupling the two RGD peptide units via Gly~3~ and PEG~4~ linkers.

Here, we radiolabelled mono-, di- and tetrameric RGD peptides with ^68^Ga and studied the tumour targeting potential of these peptides in vitro and in vivo. This is the first study in which mono-, di- and tetrameric RGD peptides labelled with ^68^Ga, for PET imaging of α~v~β~3~ expression, are directly compared with their ^111^In-labelled counterparts.

Materials and methods {#Sec2}
=====================

Synthesis of DOTA-conjugated RGD peptides {#Sec3}
-----------------------------------------

The mono-, di- and tetrameric RGD peptides were synthesised using Fmoc-based solid-phase peptide synthesis (SPPS) as described previously \[[@CR16]--[@CR19]\]. The structural formulas of DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ are shown in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1**a** Structural formula of the DOTA-conjugated monomeric RGD peptide, DOTA-E-c(RGDfK). **b** Structural formula of the DOTA-conjugated dimeric RGD peptide, DOTA-E-\[c(RGDfK)\]~2~. **c** Structural formula of the DOTA-conjugated tetrameric RGD peptide DOTA-E{E\[c(RGDfK)\]~2~}~2~

Radiolabelling of the RGD peptides {#Sec4}
----------------------------------

### ^111^In labelling {#Sec5}

DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ were radiolabelled with ^111^InCl~3~ as described previously \[[@CR17]\]. Briefly, 18.5 MBq ^111^InCl~3~ (Mallinckrodt, Petten, The Netherlands) was added to 5--20 nmol DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ dissolved in 300 or 500 μl ammonium acetate buffer, pH 6.0, containing 0.6 mg/ml gentisic acid. The mixtures were heated at 100°C for 15 min. For in vitro and in vivo studies, the reaction mixtures were diluted in phosphate-buffered saline (PBS).

### ^68^Ga labelling {#Sec6}

DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ were labelled with ^68^GaCl~3~ eluted from a TiO~2~-based 1,110 MBq ^68^Ge/^68^Ga generator (Cyclotron Co. Ltd., Obninsk, Russia) using 0.1 M HCl (Ultrapure, J.T. Baker, Deventer, The Netherlands). Five 1-ml fractions were collected and an aliquot of the second fraction was used for labelling the peptides.

^68^Ga-labelled DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ were prepared by adding 250 μl 1 M HEPES, pH 7.0, solution to 10--28 μl of the peptide dissolved (1 μg/μl) in 0.25 M ammonium acetate, pH 5.5. Then, the second millilitre eluted from the generator (315--365 MBq) was added. After 20 min at 95°C, the ^68^Ga-labelled peptides were further purified on an Oasis® HLB (1 cm^3^, 30 mg) cartridge (Waters, Milford, MA, USA). After applying the sample on the cartridge, the cartridge was washed with 3 × 1 ml H~2~O and eluted with 200 μl 25% EtOH in H~2~O (v/v). For in vitro and in vivo studies, the eluate was diluted to \<5% EtOH in PBS.

### Analysis {#Sec7}

The radiochemical purity was determined by reversed-phase high-performance liquid chromatography (RP-HPLC) on an Agilent 1100 system (Agilent Technologies, Palo Alto, CA, USA) using a C18 column (RX-C18, 4.6 × 250 mm, Zorbax) eluted with a gradient mobile phase \[0--5 min 97% buffer A, 5-15 min 97% buffer A to 0% buffer A, buffer A = 0.1% trifluoroacetic acid (TFA) in H~2~O, buffer B = 0.1% TFA in acetonitrile\] at 1 ml/min. The radioactivity of the eluate was monitored using an in-line NaI radiodetector (Raytest GmbH, Straubenhardt, Germany). Elution profiles were analysed using Gina Star software (version 2.18, Raytest GmbH, Straubenhardt, Germany). An additional quality control after purification on an HLB cartridge was performed by instant thin-layer chromatography (ITLC) using TEC-Control™ chromatography strips (Biodex Medical Systems, Shirley, NY, USA). The strips were developed using two different mobile phases. Mobile phase I was 0.1 M CH~3~COONH~4~/0.1 M EDTA (1:1 v/v) and mobile phase II was 0.25 M CH~3~COONH~4~/MeOH (1:1 v/v). The strips were analysed using a Fujifilm BAS-1800II Scanner (Fuji Photo Film Co., Tokyo, Japan).

Octanol/water partition coefficient {#Sec8}
-----------------------------------

To an Eppendorf tube filled with 0.5 ml of the radiolabelled peptide in PBS, pH 7.4, 0.5 ml octanol was added. After the tube was vigorously vortexed for 2 min at room temperature, the two layers were separated by centrifugation (100 *g*, 5 min). Then, 100-μl samples were taken from each layer and radioactivity was measured in a well-type gamma counter (Wallac Wizard 3", PerkinElmer, Waltham, MA, USA) and Log P values were calculated (*n* = 3).

In vitro stability {#Sec9}
------------------

The stability of the ^111^In- and ^68^Ga-labelled RGD peptides was determined by incubating the compounds in both PBS and human serum for 2 h at 37°C. Before analysis of the serum samples the serum proteins were precipitated by adding an equal volume of MeCN to the samples. Subsequently, serum samples were centrifuged for 5 min at 13,500 *g*. The PBS samples were analysed without any sample preparation. An aliquot of the serum and the PBS sample were injected onto HPLC.

Protein binding {#Sec10}
---------------

To determine their serum protein-binding properties, the ^68^Ga- and ^111^In-labelled peptides were incubated in fresh human serum at 37°C. After 2 h, the samples were analysed with fast protein liquid chromatography (FPLC), using a BioSep-Sec-S 3000 column (300 × 4.60 mm, Phenomenex, Utrecht, The Netherlands) with an isocratic mobile phase (PBS, 1 ml/min).

Solid-phase α~v~β~3~ binding assay {#Sec11}
----------------------------------

The affinity of Ga(III)/In(III)-DOTA-E-c(RGDfK), Ga(III)/In(III)-DOTA-E-\[c(RGDfK)\]~2~ and Ga(III)/In(III)-DOTA-E{E\[c(RGDfK)\]~2~}~2~ for α~v~β~3~ was determined using a solid-phase competitive binding assay.

For the "cold" labelling of DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ with either Ga(III) or In(III), each of the peptides was dissolved in an aqueous solution. Subsequently, a 3 M excess of InCl~3~ (Aldrich Chemical Company, Inc., Milwaukee, WI, USA) or Ga(NO~3~)~3~ (Sigma-Aldrich Chemie, Steinheim, Germany) was added. The Ga(III) or In(III) complexation was performed at room temperature overnight or at 40°C for 2 h, respectively.

^111^In-labelled DOTA-E-\[c(RGDfK)\]~2~ (3 MBq/μg) was used as the tracer in this assay. Microtiter 96-well vinyl assay plates (Corning B.V., Schiphol-Rijk, The Netherlands) were coated with 100 μl/well of a solution of purified human integrin α~v~β~3~ (150 ng/ml) in Triton X-100 Formulation (Chemicon International, Temecula, CA, USA) in coating buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl~2~, 0.5 mM MgCl~2~ and 1 mM MnCl~2~) for 17 h at 4°C. The plates were washed twice with binding buffer \[0.1% bovine serum albumin (BSA) in coating buffer\]. The wells were blocked for 2 h with 200 μl blocking buffer (1% BSA in coating buffer). The plates were washed twice with binding buffer. Then, 100 μl binding buffer containing 10 kBq of ^111^In-DOTA-E-\[c(RGDfK)\]~2~ and appropriate dilutions (2 × 10^−6^--8 × 10^−11^ M) of Ga(III)- or In(III)-labelled DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ in binding buffer were incubated in the wells at 37°C for 1 h. After incubation, the plates were washed three times with binding buffer. The wells were cut out and counted in a gamma counter. IC~50~ values of the RGD peptides were calculated by nonlinear regression using GraphPad Prism (GraphPad Prism 4.0, GraphPad Software, San Diego, CA, USA). Each data point is the average of three determinations.

Biodistribution studies {#Sec12}
-----------------------

In the right flank of 6- to 8-week-old female nude BALB/c mice, 0.2 ml of a cell suspension of 2 × 10^6^ cells/ml SK-RC-52 cells was injected subcutaneously (s.c.). Two weeks after inoculation of the tumour cells, mice were injected intravenously (i.v.) with the ^111^In- or ^68^Ga-labelled RGD peptides (0.2--0.89 nmol) in 0.2 ml PBS + 0.5% BSA. Mice were killed by CO~2~ asphyxiation 2 h post-injection (p.i.) (five mice/group). Blood, tumour and the major organs and tissues were collected, weighed and counted in a gamma counter. The percentage injected dose per gram (%ID/g) was determined for each sample.

The receptor-mediated localisation of the radiolabelled RGD peptides was investigated by determining the biodistribution of the ^111^In- or ^68^Ga-labelled compounds in the presence of an excess (100-fold excess) unlabelled DOTA-E-\[c(RGDfK)\]~2~ (*n* = 3). DOTA-E-\[c(RGDfK)\]~2~ was used for these "blocking studies" as in our previous studies this compound was demonstrated to be α~v~β~3~ specific \[[@CR20], [@CR21]\]. All animal experiments were approved by the local Animal Welfare Committee in accordance with the Dutch legislation and carried out in accordance with their guidelines.

MicroPET imaging {#Sec13}
----------------

Mice with s.c. SK-RC-52 tumours were injected i.v. with 10 MBq ^68^Ga-labelled mono-, di- or tetrameric RGD peptide per mouse (0.89 nmol). Two hours after the injection of the peptide, mice were scanned on an animal PET/CT scanner (Inveon®, Siemens Preclinical Solutions, Knoxville, TN, USA) with an intrinsic spatial resolution of 1.5 mm \[[@CR22]\]. The animals were placed in a supine position in the scanner. PET emission scans were acquired over 15 min. CT images were acquired for anatomical correlation directly after PET imaging (spatial resolution 113 μm, 80 kV, 500 μA, exposure time 300 ms).

Scans were reconstructed using Inveon Acquisition Workplace software version 1.2 (Siemens Preclinical Solutions, Knoxville, TN, USA), using an ordered subset expectation maximisation 3-D/maximum a posteriori (OSEM3D/MAP) algorithm with the following parameters: matrix 256 × 256 × 159, pixel size 0.43 × 0.43 × 0.8 mm^3^ and a beta value of 0.1.

Statistical analysis {#Sec14}
--------------------

All mean values are given ± standard deviation (SD). Statistical analysis was performed using the one-way analysis of variance. Bonferroni corrections for multiple comparisons were applied. The level of significance was set at *p* \< 0.05.

Results {#Sec15}
=======

Radiolabelling {#Sec16}
--------------

RP-HPLC analysis indicated that the radiochemical purity of the ^68^Ga- or ^111^In-labelled DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ preparations used in these experiments ranged from 93 to 97%.

The HPLC chromatograms of ^111^In-DOTA-E-c(RGDfK), ^111^In-DOTA-E-\[c(RGDfK)\]~2~ and ^111^In-DOTA-E{E\[c(RGDfK)\]~2~}~2~ showed a single peak for each of the compounds with a retention time of 14, 26 and 15 min, respectively. Note that different gradients were used.

The ITLC profiles of ^68^Ga-DOTA-E-c(RGDfK) (R~f~ = 0.35), ^68^Ga-DOTA-E-\[c(RGDfK)\]~2~ (R~f~ = 0.53) and ^68^Ga-DOTA-E{E\[c(RGDfK)\]~2~}~2~ (R~f~ = 0.08) after HLB purification demonstrated a purity of 97, 98 and 99%, respectively. The maximum specific activity of the ^68^Ga-labelled mono-, di- and tetramer was 11.2 MBq/nmol.

Octanol/water partition coefficient {#Sec17}
-----------------------------------

To determine the lipophilicity of the ^68^Ga- and ^111^In-labelled DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~, the octanol/water partition coefficients were determined. The Log P~octanol/water~ values for the ^68^Ga-labelled RGD mono-, di- and tetramer were −4.37 ± 0.13, −4.04 ± 0.15 and −3.76 ± 0.07, respectively. The Log P ~octanol/water~ values of the ^111^In-labelled RGD mono-, di- and tetramer were −4.38 ± 0.25, −3.95 ± 0.05 and −4.15 ± 0.07, respectively.

In vitro stability {#Sec18}
------------------

Determination of the stability of the ^111^In- and ^68^Ga-labelled RGD peptides indicated high stability of the compounds. There was no evidence of release of ^68^Ga or ^111^In from the peptides or radiolysis of any of the compounds in both PBS and human serum (data not shown). After 2 h incubation at 37°C more than 95% of the activity was still associated with the DOTA-conjugated cyclic peptides and no significant reduction was observed.

Protein binding {#Sec19}
---------------

No differences in the protein-binding properties between the ^68^Ga- and ^111^In-labelled RGD peptides were observed by FPLC (data not shown). The protein-bound activity was negligible (\<5%) after 2 h incubation in human serum for the ^68^Ga- as well as for the ^111^In-labelled peptides. For each of the peptides \>95% of the activity eluted as a monomeric peak at 13 min.

Solid-phase α~v~β~3~ binding assay {#Sec20}
----------------------------------

We determined the affinity of Ga(III)-DOTA-E-c(RGDfK), Ga(III)-DOTA-E-\[c(RGDfK)\]~2~ and Ga(III)-DOTA-E{E\[c(RGDfK)\]~2~}~2~ and their In(III)-labelled analogues for integrin α~v~β~3~ in a competitive binding assay. The results of these assays are summarised in Fig. [2](#Fig2){ref-type="fig"}. Binding of ^111^In-labelled dimeric peptide, ^111^In-DOTA-E-\[c(RGDfK)\]~2~, to α~v~β~3~ was competed by Ga(III)- or In(III)-labelled DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ in a concentration-dependent manner. The IC~50~ values were 23.9 ± 1.22 nM, 8.99 ± 1.20 nM and 1.74 ± 1.18 nM for Ga(III)-labelled DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~, respectively (Table [1](#Tab1){ref-type="table"}). The affinities of the In(III)-labelled mono-, di- and tetrameric RGD peptides were similar: 26.6 ± 1.15 nM, 3.34 ± 1.16 nM and 1.80 ± 1.37 nM, respectively. Fig. 2Competition of specific binding of ^111^In-DOTA-E-\[c(RGDfK)\]~2~ with Ga(III)-DOTA-E-c(RGDfK), Ga(III)-DOTA-E-\[c(RGDfK)\]~2~ and Ga(III)-DOTA-E{E\[c(RGDfK)\]~2~}~2~Table 1IC~50~ values arising from a competitive binding assay of Ga(III)- and In(III)-labelled RGD mono-, di- and tetramerCompoundGa(III)-labelled ± SD (nM)In(III)-labelled ± SD (nM)Monomer23.9 ± 1.2226.6 ± 1.15Dimer8.99 ± 1.203.34 ± 1.16Tetramer1.74 ± 1.181.80 ± 1.37

Biodistribution studies {#Sec21}
-----------------------

The results of the biodistribution studies of both ^111^In- and ^68^Ga-labelled DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ are summarised in Fig. [3](#Fig3){ref-type="fig"}. DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ radiolabelled with either ^68^Ga or ^111^In all cleared rapidly from the blood. At 2 h p.i. the blood level of all compounds was below 0.4%ID/g. Tumour uptakes of the ^68^Ga-labelled mono-, di- and tetrameric RGD peptides (3.30 ± 0.30, 5.24 ± 0.27 and 7.11 ± 0.67%ID/g, respectively) were comparable to those of their ^111^In-labelled counterparts (2.70 ± 0.29, 5.61 ± 0.85 and 7.32 ± 2.45%ID/g, respectively). At 2 h p.i., the tumour uptake was significantly higher for the ^68^Ga-labelled tetramer (7.11 ± 0.67%ID/g), compared to that of the dimer (5.24 ± 0.27%ID/g) and that of the monomer (3.30 ± 0.30%ID/g). For the ^111^In-labelled analogues, there was no difference in tumour uptake between the tetramer (7.32 ± 2.45%ID/g) and dimer (5.61 ± 0.85%ID/g), whereas the tumour uptake of the ^111^In-labelled dimer was significantly higher than that of the ^111^In-labelled monomer (2.70 ± 0.29%ID/g). Fig. 3**a** Biodistribution of \[^68^Ga\]DOTA-E-c(RGDfK), \[^68^Ga\]DOTA-E-\[c(RGDfK)\]~2~ and \[^68^Ga\]DOTA-E{E\[c(RGDfK)\]~2~}~2~ at 2 h p.i. in athymic mice with s.c. SK-RC-52 tumours in the absence (five mice/group) or presence (three mice/group) of an excess of DOTA-E-\[c(RGDfK)\]~2~. **b** Biodistribution of \[^111^In\]DOTA-E-c(RGDfK), \[^111^In\]DOTA-E-\[c(RGDfK)\]~2~ and \[^111^In\]DOTA-E{E\[c(RGDfK)\]~2~}~2~ at 2 h p.i. in athymic mice with s.c. SK-RC-52 tumours in the absence (five mice/group) or presence (three mice/group) of an excess of DOTA-E-\[c(RGDfK)\]~2~

Coinjection of an excess unlabelled DOTA-E-\[c(RGDfK)\]~2~ (50 μg) along with 0.5 μg of ^68^Ga- or ^111^In-labelled DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ or DOTA-E{E\[c(RGDfK)\]~2~}~2~ resulted in a significantly reduced radioactivity concentration in the tumour, indicating that uptake of the major fraction of DOTA-E-c(RGDfK), DOTA-E-\[c(RGDfK)\]~2~ and DOTA-E{E\[c(RGDfK)\]~2~}~2~ in the tumour was α~v~β~3~ mediated. Uptake in nontarget organs such as lung, spleen and intestine was also reduced in the presence of an excess of unlabelled RGD peptide, indicating that the uptake in these tissues was at least partly α~v~β~3~ mediated. The kidney uptake of the ^68^Ga- and ^111^In-labelled monomer and dimer could partly be blocked. However, renal uptake of the ^68^Ga- and ^111^In-labelled tetramer could not be blocked. Kidney uptake was remarkably high for the ^68^Ga-labelled tetramer compared to its ^111^In-labelled analogue.

Fused PET and CT scans are shown in Fig. [4](#Fig4){ref-type="fig"}. PET scans were in line with the biodistribution data. On all PET scans, the tumour could be clearly visualised. The ^68^Ga-labelled tetramer showed the highest tumour uptake compared to the monomer and dimer. All three tracers showed some uptake in the kidneys, especially the tetramer. On the other hand, the monomer demonstrated relatively high intestinal uptake. The ^68^Ga-labelled tetramer showed the highest tumour to background ratio and therefore this tracer is the most suitable for imaging α~v~β~3~ expression by PET. Fig. 4Anterior 3-D volume rendering projections of fused PET and CT scans of mice with a s.c. growing SK-RC-52 tumour after i.v. injection of \[^68^Ga\]DOTA-E-c(RGDfK) (**a**), \[^68^Ga\]DOTA-E-\[c(RGDfK)\]~2~ (**b**) or \[^68^Ga\]DOTA-E{E\[c(RGDfK)\]~2~}~2~ (**c**). Scans were recorded at 2 h p.i.

Discussion {#Sec22}
==========

In this study, the feasibility of using ^68^Ga-labelled multimeric RGD peptides for radionuclide imaging of the α~v~β~3~ integrin expression with PET was investigated. The radiolabelled mono-, di and tetrameric RGD peptides were very hydrophilic as demonstrated by their partition coefficients (Log P~octanol/water~). The Log P values varied between −4.38 ± 0.25 for the ^111^In-labelled monomer and −3.76 ± 0.07 for the ^68^Ga-labelled tetramer. These values are even lower than the value found for \[^18^F\]Galacto-RGD (Log P = −3.2) which is cleared almost exclusively via the kidneys \[[@CR23]\]. The hydrophilicity of the ^68^Ga-labelled monomer and dimer labelled with either ^68^Ga or ^111^In was not different. Only for the tetramer was the Log P value lower for the ^111^In-labelled variant compared to its ^68^Ga-labelled counterpart. Heppeler et al. demonstrated that for the complexation of gallium by DOTA four nitrogen atoms of the macrocycle and two oxygen atoms from the carboxylate groups are involved \[[@CR24]\]. Thus, one carboxylic acid group of the DOTA chelator is not involved in complexation of ^68^Ga. However, for ^111^In it is assumed that the four nitrogen atoms of the DOTA macrocycle and the four oxygen atoms of the carboxylic groups are involved in the complexation. Despite the fact that the ^68^Ga-DOTA complex has one more carboxylic acid group that is not involved in the complexation compared to the ^111^In-DOTA complex, the ^68^Ga-labelled analogue does not have an increased hydrophilicity.

The binding affinity of Ga(III)-DOTA-tetramer (IC~50~ = 1.74 ± 1.18 nM), as determined in a solid-phase competitive binding assay, was about 5 times higher compared to Ga(III)-DOTA-dimer (IC~50~ = 8.99 ± 1.20 nM) and about 13 times higher compared to Ga(III)-DOTA-monomer (IC~50~ = 23.9 ± 1.22 nM). The binding affinity of the In(III)-labelled monomeric (26.6 ± 1.15 nM), dimeric (3.34 ± 1.16 nM) and tetrameric RGD peptides (1.80 ± 1.37 nM) was comparable.

In the s.c. SK-RC-25 renal cell carcinoma xenograft model, the tetrameric RGD peptide, labelled with either ^68^Ga or ^111^In, showed the highest tumour uptake. Thus, there is a relation between the binding affinity for α~v~β~3~ and the accumulation of the compound in α~v~β~3~-expressing tumours. All three RGD peptides of this study labelled with either ^68^Ga or ^111^In showed specific tumour uptake in athymic mice with s.c. SK-RC-52 tumours: in the presence of an excess of unlabelled DOTA-E-\[c(RGDfK)\]~2~, the specificity of the tumour targeting of the monomeric, dimeric, and tetrameric RGD peptides was evident.

Several research groups have applied the multivalent concept to prepare cyclic RGD peptides with an enhanced binding affinity and demonstrated that the multimeric RGD peptides have an enhanced localisation in α~v~β~3~-expressing tumours \[[@CR17], [@CR19], [@CR25]--[@CR30]\]. Although the advantages of multimeric RGD peptides as targeting molecules are universally accepted, the cause of the enhanced affinity of the multimeric RGD analogues for integrin α~v~β~3~ is still a matter of debate \[[@CR31]\]. Cells can form a cluster of many monovalent receptors on the cell surface \[[@CR32]\], and particularly multimeric ligands with a spacer between the binding moieties could span the required distance between binding sites and could then bind multiple receptors simultaneously. On the other hand, multimeric compounds could have enhanced affinity due to statistical rebinding: the receptor binding of one RGD unit will significantly enhance the local concentration of the second RGD unit in the vicinity of the receptor. This could lead to an enhanced α~v~β~3~-binding rate or a reduced α~v~β~3~-dissociation rate of the RGD multimer \[[@CR19]\]. The distance between the RGD units of the multimers used in this study is relatively short and therefore statistical rebinding might be the most likely explanation for the increased affinity in the series tetramer \> dimer \> monomer.

The three ^68^Ga-labelled RGD peptides showed a remarkable difference in kidney uptake. The uptake of the ^68^Ga-labelled tetrameric RGD peptide was at 2 h p.i. significantly higher than that of the ^68^Ga-labelled dimer and monomeric RGD peptides. In the integrin specificity experiment, the excess of nonradiolabelled RGD peptide partly inhibited the kidney uptake of the radiolabelled monomer and dimer, but not the kidney uptake of the radiolabelled tetramer. This indicates that different mechanisms cause the relatively high uptake of the RGD peptides in the kidneys. Wu and coworkers have recently shown by immunohistochemistry that the endothelial cells of the glomeruli vessels in the kidneys express β~3~ integrins \[[@CR33]\], which could explain the partly specific kidney uptake of the RGD peptide. Furthermore, the difference in charge between the three peptides could cause the difference in tubular reabsorption. A trend has been observed that positively charged peptides are more efficiently reabsorbed by the proximal renal tubular cell than neutral peptides \[[@CR34]\]. Due to the presence of more guanidine groups, the tetrameric RGD peptide is more positively charged than the dimeric and monomeric RGD peptides. Remarkably, the ^68^Ga-labelled tetramer demonstrated a much higher kidney uptake than the ^111^In-labelled tetramer which may hamper its clinical application.

Other nontumour tissues such as lung, liver and colon also showed specific uptake of the mono-, di- and tetrameric RGD peptides, suggesting α~v~β~3~ expression in these tissues. Indeed, β~3~ expression in these tissues has been described for rodents as well as for humans \[[@CR33], [@CR35]\]. Decristoforo and coworkers compared the biodistribution of \[^68^Ga\]DOTA-RGD, \[^111^In\]DOTA-RGD and \[^18^F\]Galacto-RGD and found that \[^68^Ga\]DOTA-RGD had the highest tracer uptake in all organs \[[@CR13]\]. Especially, the radioactivity concentration in the blood was significantly higher for \[^68^Ga\]DOTA-RGD compared with \[^111^In\]DOTA-RGD. The authors hypothesised that the lower complex stability of the ^68^Ga-DOTA complex could result in transchelation of gallium to transferrin. In our study, the ^68^Ga-labelled peptides, especially the dimer and tetramer, did not show enhanced blood levels as compared to the ^111^In-labelled counterparts. In addition, in our in vitro studies no evidence of instability of the ^68^Ga-DOTA complex or protein-binding activity was observed. This is in line with the recent observation of Haukkala and coworkers who found that there was no evidence of dissociation of ^68^Ga from DOTA in the blood \[[@CR36]\]. Although DOTA has a larger cavity than NOTA and the log stability constants are in favour of the Ga-NOTA complex compared with the Ga-DOTA complex \[[@CR37], [@CR38]\], the ^68^Ga-DOTA complex is stable enough for in vitro and in vivo studies.

In conclusion, the tetrameric RGD peptide demonstrated improved tumour targeting compared to the dimeric RGD peptide. Analogously, the dimeric RGD peptide exhibits improved tumour targeting compared to the monomeric RGD peptide. The results of the biodistribution study of the ^68^Ga- and ^111^In-labelled dimer and tetramer are rather comparable. The ^68^Ga-labelled tetrameric RGD peptide is a suitable ligand for the noninvasive visualisation of α~v~β~3~ expression in vivo.
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